The New Drug Wars Are Looking At The Wrong Enemy stat : good
"That was patently false and that was propagated by what I call 'big medicine,' in cahoots with Big Pharma."The prescription addiction epidemic is fraught with complexity. One of the easiest and more effective things the U.S. government can invest more in instead of a border wall are state-run Prescription Drug Monitoring Programs. If....the wall is not built, which it will be, the drug situation will NEVER be fixed the way it should be! Trump's tweets highlight one thing: He's totally ignorant on how to actually fix the drug problem in America. And in the excellent news department, in early April, Health and Human Services secretary Tom Price announced that states will be getting $485 million in grant money for PDMP and further prescription drug treatment programs.
What management had to sayBiogen CEO Michel Vounatsos gave some interesting stats that show the potential to grow Spinraza sales substantially from here. In the nearer term, the next big thing from Biogen could be its Alzheimer's disease drug aducanumab, which is in phase 3 development. Sales of Spinraza came in at $47 million during the first full quarter of the drug on the market. Some leading centers are already dosing more than 10 patients, but most sites have only dosed 1 or 2 patients so far. Biogen (NASDAQ:BIIB) reported first-quarter earnings on Tuesday, resulting in investors excited about the potential for Spinraza, its new spinal muscular atrophy drug developed with Ionis Pharmaceuticals (NASDAQ:IONS), but tolerating ho-hum sales growth of its multiple sclerosis drugs.
A deadly synthetic addiction powerful enough to tranquilize elephants has been linked to three overdose deaths in New Hampshire, marking one of its first confirmed appearances in New England. The drug has been linked to deaths in the Midwest, and the Drug Enforcement Agency issued a public warning about it in September. Chris Sununu said Tuesday the drug carfentanil was the cause of deaths for two men in Manchester and one man in Meredith, all in March. No arrests have been made linked to the New Hampshire deaths, but investigations into where the drug came from and who sold it are underway. Carfentanil was created to tranquilize large animals and is 100 times more potent than fentanyl, the drug responsible for most of New Hampshire's 500 overdose deaths last year, state officials said.
collected by :Lucy William
What management had to sayBiogen CEO Michel Vounatsos gave some interesting stats that show the potential to grow Spinraza sales substantially from here. In the nearer term, the next big thing from Biogen could be its Alzheimer's disease drug aducanumab, which is in phase 3 development. Sales of Spinraza came in at $47 million during the first full quarter of the drug on the market. Some leading centers are already dosing more than 10 patients, but most sites have only dosed 1 or 2 patients so far. Biogen (NASDAQ:BIIB) reported first-quarter earnings on Tuesday, resulting in investors excited about the potential for Spinraza, its new spinal muscular atrophy drug developed with Ionis Pharmaceuticals (NASDAQ:IONS), but tolerating ho-hum sales growth of its multiple sclerosis drugs.
A deadly synthetic addiction powerful enough to tranquilize elephants has been linked to three overdose deaths in New Hampshire, marking one of its first confirmed appearances in New England. The drug has been linked to deaths in the Midwest, and the Drug Enforcement Agency issued a public warning about it in September. Chris Sununu said Tuesday the drug carfentanil was the cause of deaths for two men in Manchester and one man in Meredith, all in March. No arrests have been made linked to the New Hampshire deaths, but investigations into where the drug came from and who sold it are underway. Carfentanil was created to tranquilize large animals and is 100 times more potent than fentanyl, the drug responsible for most of New Hampshire's 500 overdose deaths last year, state officials said.
collected by :Lucy William
Comments
Post a Comment